NCT00359983 - Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB | Biotech Hunter

Enrollment

270

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

May 31, 2011

Conditions

Neisseria MeningitidisHaemophilus Influenzae Type b

Interventions

BIOLOGICAL

MenHibrix (Hib-MenCY-TT)

First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose

BIOLOGICAL

Hib conjugate vaccine (ActHIB)

First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose

Trial Locations (21)

14534

GSK Investigational Site, Pittsford

14620

GSK Investigational Site, Rochester

15217

GSK Investigational Site, Pittsburgh

15236

GSK Investigational Site, Pittsburgh

15241

GSK Investigational Site, Pittsburgh

16125

GSK Investigational Site, Greenville

16505

GSK Investigational Site, Erie

30062

GSK Investigational Site, Marietta

30189

GSK Investigational Site, Woodstock

40004

GSK Investigational Site, Bardstown

40202

GSK Investigational Site, Louisville

40272

GSK Investigational Site, Louisville

44121

GSK Investigational Site, Cleveland

44512

GSK Investigational Site, Boardman

50263

GSK Investigational Site, Waukee

71111

GSK Investigational Site, Bossier City

72205

GSK Investigational Site, Little Rock

92708

GSK Investigational Site, Fountain Valley

06360

GSK Investigational Site, Norwich

02118

GSK Investigational Site, Boston

02724

GSK Investigational Site, Fall River